The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results were announced in a news release […]
The post Alzheimer’s drug slowed progression of the disease in Phase 3 trial appeared first on The Black Chronicle.
